Lipid conjugates in the treatment of chronic rhinosinusitis
View Patent ↗This invention provides a method of treating, suppressing, inhibiting, or preventing chronic rhinosinusitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating, suppressing, inhibiting, or preventing nasal polyps in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
1. A method of treating or preventing chronic rhinosinusitis in a subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (A):
wherein
L is a phospholipid;
Z is nothing;
Y is nothing;
X is a glycosaminoglycan; and
n is a number from 1 to 1000.
2. The method according to claim 1 wherein said glycosaminoglycan is selected from the group consisting of hyaluronic acid, heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, and dermatan sulfate or a derivative thereof.
3. The method according to claim 1 , wherein L is phosphatidylethanolamine.
4. The method according to claim 3 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
5. The method according to claim 1 , wherein said chronic rhinosinusitis is chronic rhinosinusitis with polyps.
6. A method of treating or preventing nasal polyps in a subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (A):
wherein
L is a phospholipid;
Z is nothing;
Y is nothing;
X is a glvcosaminoglycan; and
n is a number from 1 to 1000.
7. The method according to claim 6 , wherein said glycosaminoglycan is selected from the group consisting of hyaluronic acid, heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, and dermatan sulfate or a derivative thereof.
8. The method according to claim 6 , wherein L is a phosphatidylethanolamine.
9. The method according to claim 8 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
10. The method according to claim 1 , wherein said compound is represented by the structure of the general formula (I):
wherein
R 1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R 2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
Y is nothing;
X is glycosaminoglycan; and
n is a number from 1 to 1,000.
11. The method of claim 10 , wherein said glycosaminoglycan is selected from the group consisting of hyaluronic acid, heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, dermatan sulfate or a derivative thereof.
12. The method of claim 1 , wherein said glycosaminoglycan has a molecular weight of between 5 kD and 90 kD.
13. The method of claim 1 , wherein said glycosaminoglycan has a molecular weight of between 5 kD and 20 kD.
14. The method according to claim 6 , wherein said compound is represented by the structure of the general formula (I):
wherein
R 1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R 2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
Y is nothing;
X is glycosaminoglycan; and
n is a number from 1 to 1,000.
15. The method of claim 14 , wherein said glycosaminoglycan is selected from the group consisting of hyaluronic acid, heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, dermatan sulfate or a derivative thereof.
16. The method of claim 14 , wherein said glycosaminoglycan has a molecular weight of between 5 kD and 20 kD.
17. The method of claim 10 , wherein n is a number from 2 to 500.
18. The method of claim 14 , wherein n is a number from 2 to 500.
19. The method of claim 1 , wherein the step of administering comprises nasal administration.
20. The method of claim 6 , wherein the step of administering comprises nasal administration.